Novartis is seeking to repurpose its investigational oral spinal muscular atrophy (SMA) drug branaplam to treat Huntington's disease, the Swiss drugmaker said on Wednesday, as it plans a clinical ...
Spinal muscular atrophy affects all the body's muscles. For a long time, it was considered a disease caused solely by the ...
Spinal muscular atrophy (SMA) is a severe neurological disease for which there is presently no cure, although current therapies can alleviate symptoms. In the search for better treatment options, ...
In a closely watched case, Roche suffered a setback as a court said it would permit a generic version of its rare disease ...
FOX 9 Minneapolis-St. Paul on MSN
Coon Rapids family fights rare genetic disease to save daughter's life
As their 8-month-old daughter prepares for gene therapy treatment, a Coon Rapids family is bracing for three months of ...
Affordable Risdiplam is now within reach for Spinal Muscular Atrophy (SMA) patients in India, thanks to a Delhi High Court ...
According to the National Institute of Neurological Disorders and Stroke, there are currently only three FDA-approved ...
The Delhi High Court has dismissed Roche's appeal, allowing Natco to launch a generic version of Risdiplam for spinal ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
Spinal muscular atrophy (SMA) is a severe neurological disease for which there is presently no cure, although current therapies can alleviate symptoms. In the search for better treatment options, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback